Zura Bio Limited

NasdaqCM ZURA

Zura Bio Limited Price to Sales Ratio (P/S) on January 14, 2025

Zura Bio Limited Price to Sales Ratio (P/S) is NA on January 14, 2025, a NA change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Zura Bio Limited 52-week high Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • Zura Bio Limited 52-week low Price to Sales Ratio (P/S) is NA on January 14, 2025, which is NA below the current Price to Sales Ratio (P/S).
  • Zura Bio Limited average Price to Sales Ratio (P/S) for the last 52 weeks is NA.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
NasdaqCM: ZURA

Zura Bio Limited

CEO Mr. Robert Lisicki
IPO Date March 21, 2023
Location United States
Headquarters 4225 Executive Square
Employees 14
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

StockViz Staff

January 15, 2025

Any question? Send us an email